Clinical trials: Pleural Mesotheliomas
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Background: Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.
- Conditions
- Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS
- Trial name
- NCT00242723
- Where
- United States
- Volunteers
- 1,559 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia, Multiple Myeloma
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk.
- Conditions
- Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma
- Trial name
- IT-TCP POS (NCT07403630)
- Testing
- Functional tests, Multi-omics analyses, Cytogenetics/ FISH
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Malignant Mesothelioma
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinorelbine, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354393
- Testing
- Cisplatin, Methotrexate, Vinorelbine ditartrate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Malignant Pleural Mesothelioma
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
This study will examine the safety and potential effectiveness of poly-ICLC directly injected into malignant pleural mesothelioma at the time of biopsy up to 21 days prior to the cancer being removed by the surgeon
- Trial name
- NCT04525859
- Testing
- Safety, Expansion Cohort
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Oncovir, Inc.
Mesothelioma, Mesothelioma Malignant
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Mesothelioma, Mesothelioma Malignant, Mesothelioma; Lung, Mesotheliomas Pleural
- Trial name
- NCT04214015
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Pretreated Pleural Mesothelioma
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
This study is a prospective, multicenter, single-arm, Phase II clinical trial evaluating the efficacy and safety of ivonescimab (AK112) combined with chemotherapy in patients with pleural mesothelioma who failed prior…
- Trial name
- NCT06875076
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Hospital of Jilin University
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Non Small Cell Lung Cancer, Malignant Pleural Mesothelioma
Alvopem® (Pemetrexed) Safety Assessment
The present study was a phase IV, post-marketing, observational study for safety evaluation of Alvopem® use in Iranian patients with non-small cell lung cancer and malignant pleural mesothelioma.
- Trial name
- NCT04843007
- Testing
- Pemetrexed
- Volunteers
- 199 people
- Sponsor
- NanoAlvand
Malignant Pleural Mesothelioma
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on…
- Trial name
- NCT01865045
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Armando Santoro, MD
Malignant Pleural Mesothelioma, Chemotherapy Effect
Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Median survival from diagnosis is less than 12 months (1).
- Trial name
- NCT05508555
- Testing
- hyperthermic intrathoracic chemotherapy
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Peritoneum Cancer, Peritoneum Neoplasm
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases.
- Conditions
- Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural Effusion
- Trial name
- PIPACRegis (NCT03210298)
- Testing
- PIPAC
- Where
- 16 sites in Argentina, Australia and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Sabine Rhode
Mesothelioma, Lung Neoplasms
Chest Wall Motion Analysis in Disease
Breathing movements, called chest wall motion, are very complex. The investigators are studying how movement of the abdomen, ribs and diaphragm contribute to breathing and how this differs with different diseases in the chest.
- Conditions
- Mesothelioma, Lung Neoplasms, Surgery, Cystic Fibrosis
- Trial name
- CWM (NCT02958683)
- Testing
- Chest wall motion analysis
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Heart of England NHS Trust
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Malignant (Pleural) Mesothelioma
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients.
- Trial name
- PMR-MM-002 (NCT01241682)
- Testing
- DC + CTX
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00039182
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227630
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 8 sites in Belgium, Italy and 2 more
- Volunteers
- 59 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Mesothelioma, Metastatic Cancer
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00899613
- Testing
- laboratory biomarker analysis, study of high risk factors
- Where
- France
- Volunteers
- 270 people
- Sponsor
- University Hospital, Caen